Join the club for FREE to access the whole archive and other member benefits.

First-ever true clinical trial to slow down ageing in dogs


Key points from article :

The Dog Aging Project aims to demonstrate dogs as a compelling model for aging and age-related disease in humans.

Started a clinical trial using rapamycin in healthy dogs to show improvement in lifespan and healthspan.

Matt Kaeberlein believes that rapamycin is the best shot for a longevity intervention in a clinical trial.

Trial comes after two short-term pilot studies in dogs, predominantly to show safety data.

The 3-year study focuses on seven year old healthy dogs weighing at least 40 pounds at the time of enrolment.

Following a recent donation, the trial is now extended to around 600 dogs.

“This is really the first true clinical trial for aging or longevity, because this is a healthy aging study,” says Kaeberlein.

Lifespan is the primary endpoint; multiple secondary endpoints include heart function, cognitive function, kidney function and activity.

Kaeberlein hopes a positive trial in dogs would have a broader impact on the field of aging and geroscience in general.

A rapamycin trial testing healthspan improvements in dogs; results may extrapolate to humans as well

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Health Organisation

Helping dogs and people increase healthspan


Professor at University of Washington and chair of the American Aging Association